WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

Artificial Intelligence-Driven Molecular Design and Nanocarrier-Based Drug Delivery: A New Era in Medicinal Chemistry

Danuish. K*, Jayakumar. A, Karthi. J.

Department of Pharmaceutical Chemistry.
Pallavan Pharmacy College, Kanchipuram, INDIA.

ABSTRACT :

Artificial intelligence (AI) has emerged as a transformative force in medicinal chemistry, enabling rapid molecular design, target identification, and property prediction. Generative AI models and reinforcement learning now facilitate de novo drug design of small molecules and peptides with improved pharmacokinetic and safety profiles (1). In parallel, nanocarrier-based drug delivery systems including lipid nanoparticles (LNPs), polymeric micelles, and dendrites-have revolutionized the delivery of nucleic acid therapeutics, as demonstrated by SiRNA (Parisian) and mRNA vaccines (6). Recent advances highlight the integration of AI with nanotechnology: AI-driven optimization of lipid composition, microfluidic-assisted formulation, and predictive modelling of organ- and cell-specific delivery (8). This synergy accelerates discovery pipelines, enhances safety, and enables personalized nanomedicine with improved clinical translation. Despite challenges such as data scarcity, model generalizability, and regulatory hurdles, the convergence of AI and nanocarriers defines a new era in drug discovery and delivery with broad implications for oncology, neurology, and infectious diseases (10).

KEYWORDS: Molecular design, nanocarriers, artificial intelligence, drug discovery, medicinal chemistry.

INTRODUCTION

Medicine discovery and development remain lengthy, precious, and high-trouble processes, with estimates suggesting that bringing a single new molecular entity to request requires over a decade of exploration and billions of dollars in investment (11). Traditional approaches counting on high-outturn network and empirical medicinal chemistry constantly face high waste rates due to poor pharmacokinetic properties, off-target bane, and delivery limitations (12). In recent times, artificial intelligence (AI) has surfaced as an important tool to accelerate and optimize molecular design. Machine learning (ML) and deep learning algorithms can prognosticate physicochemical properties, model protein–ligand relations, and indeed induce new composites de novo (1,10). Generative models, similar to intermittent neural networks (RNNs), variational autoencoders (VAEs), and bolstering knowledge fabrics, have enabled the discovery of structurally different motifs with optimized medicine-like parcels, reducing dependence on brute-force network (2,3). Also, advancements similar to AlphaFold have revolutionized structural biology by prognosticating protein folding with remarkable delicacy, further empowering structure-based drug design. Resembling computational advances, nanotechnology-based medicine delivery systems have converted remedial strategies. Nanocarriers, including lipid nanoparticles (LNPs), polymeric nanoparticles, dendrimers, and inorganic systems, offer unique advantages such as enhanced solubility, controlled release, targeted delivery, and reduced systemic bane (9). The clinical blessing of patisiran, the first small interfering RNA (siRNA) medicine delivered via LNPs, and the global success of mRNA vaccines during the COVID-19 epidemic demonstrate the translational power of nanomedicine (4). AI can optimize both the remedial patch and its carrier by prognosticating nanocarrier composition, stability, biodistribution, and immunogenicity, thereby accelerating the design – make – test cycle (7). This community paves the way for substantiated nanomedicine, in which computationally designed medicines are paired with acclimated nanocarriers to maximize effectiveness and minimize adverse effects. This review highlights the state-of-the-art in AI-driven molecular design and nanocarrier-grounded delivery, discusses their integration, and outlines future perspectives and challenges for clinical translation.

AI-DRIVEN MOLECULAR DESIGN

Generative Models for De Novo Design:

Recent advances in generative AI — including intermittent neural networks (RNNs), variational autoencoders (Vans), generative inimical networks (GANs), prolixity models, and underpinning learning — enable the design of new motes with specific physicochemical and pharmacological parcels (1,3). Unlike traditional webbing, these models explore vast chemical space efficiently, creating seeker structures conditioned on medicine-likeness, binding affinity, or ADMIT (immersion, distribution, metabolism, excretion, toxin) biographies. For case, underpinning learning fabrics similar as REINVENT have been successfully used to optimize lead composites in silicon before experimental confirmation (2).

Predictive Modeling for ADMIT and poison:

AI models are now routinely applied to prognosticate ADMIT parcels, significantly reducing late-stage failures. Machine knowledge algorithms can read oral bioavailability, blood – brain barricade permeability, cardiotoxicity (e.g., her inhibition), and metabolic stability, enabling the prioritization of safe and effective contenders beforehand in discovery channels (13).

AI Beyond Small motes:

In addition to traditional small motes, AI- driven design is being extended to biologics similar as peptides, proteins, and nucleic acids. Deep generative models can optimize peptide sequences for stability and particularity, design novel protein pulpits, and indeed suggest variations to mRNA sequences to enhance restatement effectiveness and stability — areas directly applicable to nanocarrier- grounded delivery systems (14).

Structure-Grounded and Data-Driven Design:

AI has also enhanced structure-grounded medicine design (SBDD) by integrating protein – ligand commerce data with prophetic modeling. The advance of AlphaFold in protein structure vaccination has revolutionized medicine design by furnishing largely accurate three-dimensional structures of preliminarily characterized targets (15). Coupled with docking simulations and machine literacy-based scoring functions, these models accelerate the identification of promising lead molecules.
Overall, AI-driven molecular design represents a paradigm shift from trial-and-error trial to rational, data-driven, and prophetic approaches that synergize with nanocarrier technologies for coming-generation rectifiers.

NANOCARRIER-BASED DRUG DELIVERY

Polymeric Nanoparticles:

Biodegradable polymers similar as poly (lactic-co-glycolic acid) (PLGA), polyethylene glycol(cut), and chitosan are considerably used for controlled drug release. These carriers cover drugs from enzymatic declination, give sustained release, and can be face- functionalized for active targeting. Polymeric micelles further enhance the solubility of hydrophobic drugs and have been explored in oncology and neurological operations (9).

Lipid Nanoparticles (LNPs):

LNPs represent the most clinically advanced nanocarriers. They are composed of ionizable lipids, coadjutor phospholipids, cholesterol, and polyethylene glycol(cut)- lipids, forming stable vesicles that synopsize nucleic acids or small motes (5). LNPs give high encapsulation effectiveness and effective endosome escape, making them the backbone of SiRNA delivery (Parisian/ ONPATTRO) and mRNA vaccines against COVID- 19 (4). Ongoing exploration focuses on tuning lipid structure, PKA, and cut viscosity to ameliorate stability, reduce immunogenicity, and achieve extrahepatic targeting (6).

Inorganic and Hybrid Nanocarriers:

Inorganic nanoparticles similar to gold, silica, and iron oxide offer unique functionalities including imaging, photothermal remedy, and magnetically guided delivery. Mongrel nanocarriers combining lipids with polymers or inorganic factors aim to integrate stability, responsiveness, and multifunctionality into a single delivery system (16).

Dendrimers:

Dendrimers are largely fanned, monodisperse polymers with tunable face chemistry that enables multiagent medicine lading and targeted ligand attachment. Their well-defined structure and nanoscale size allow precise control over pharmacokinetics, though issues similar as cytotoxicity and high manufacturing costs remain barriers to wide clinical restatement (18).

Stimuli- Responsive Systems:

Arising designs influence stimulants responsive release mechanisms, where medicine release is touched off by changes in pH, temperature, redox state, enzymatic exertion, or external fields (light, ultrasound, glamorous) (17). similar" smart" nanocarriers ameliorate point-specific medicine activation and reduce systemic exposure, making them largely seductive for cancer remedy and central nervous system (CNS) delivery.
Together, these platforms punctuate the versatility of nanocarriers in delivery walls, enabling clinical restatement of rectifiers that would else fail due to insecurity or poor pharmacokinetics.



FIGURE 1: Nanocarrier Based Drug Delivery

AI MEETS NANOCARRIERS

Co-Design of Molecule and Vehicle:

The community between artificial intelligence (AI)- driven medicine discovery and nanocarrier engineering is transubstantiating the geography of perfection drug. Traditionally, medicine design and expression development were successional processes motes were discovered first, and only latterly optimized for delivery. This siloed approach frequently redounded in promising medicine campaigners failing due to poor bioavailability, insecurity, or off- target goods. AI now enables theco-design of remedial motes alongside their delivery vehicles, creating a more intertwined and effective medicine development channel (19).

AI for Nanocarrier Material Discovery:

Machine literacy (ML) and deep literacy (DL) models are being applied to prognosticate the physicochemical parcels, stability, and biocompatibility of nanocarrier accouterments. For example, generative AI algorithms can design new lipids for lipid nanoparticles (LNPs) optimized for mRNA delivery. Also, ML- guided webbing accelerates the discovery of biodegradable polymers with acclimatized release kinetics (20).

AI- Guided individualized Nanomedicine:

AI also supports the design of substantiated nanocarrier systems by integrating case-specific genomic, proteomic, and metabolomic data. This enables adaptive phrasings where both the molecular medicine structure and nanocarrier composition are optimized for individual cases (21). Similar approaches are particularly promising in oncology and rare inheritable diseases, where variability in patient response remains a crucial challenge.

AI for medicine – Carrier Matching:

One major challenge in nanomedicine is relating the most suitable carrier for a specific remedial. AI can prognosticate medicine – carrier relations, encapsulation effectiveness, and release biographies by assaying large datasets of nanocarrier compositions and performance issues (22). For illustration, graph neural networks (GNNs) have been applied to model nanoparticle – protein nimbus conformation, which critically influences biodistribution and vulnerable response (23).



FIGURE 2: Co-Design of molecule and vehicle

CHALLENGES IN MEDICINAL CHEMISTRY AND AI-NANOCARRIER DRUG DELIVERY

Target Identification and Validation:

Medicinal chemistry frequently struggles with relating and validating robust medicine targets. Complex conditions similar as cancer, Alzheimer's, and autoimmune diseases involve multiple molecular pathways, making it delicate to design single-target medicines (24).

Data Quality and Vacuity for AI Models:

AI- driven molecular design requires large, different, and high-quality datasets. Unfortunately, biomedical data is frequently fractured, personal, or prejudiced, limiting the robustness and generalizability of AI prognostications (10).

Manufacturing and Scalability of Nanocarriers:

Indeed, when AI identifies promising nanocarrier phrasings, large-scale product with harmonious quality remains a chain. Issues such as stability, reproducibility, and GMP compliance disguise barriers to commercialization (25).

Antimicrobial Resistance (AMR):

In the sphere of contagious conditions, the rise of antimicrobial resistance has outpaced medicine discovery. While AI may accelerate identification of new antibiotics, the chemical and natural complexity of resistant pathogens still challenges medicinal chemistry (26).

CONCLUSION

The intersection of AI-based molecular design and nanocarrier-supported medicine delivery is transforming medicinal chemistry. AI speeds up drug discovery by navigating extensive chemical space and predicting outcomes, while nanocarriers improve treatment delivery with accuracy and precision. Despite challenges such as data constraints, scalability issues, and unsupervised barriers, this community shows significant promise for validated and efficient treatments. AI and nanotechnology, in conjunction, signify a new era in the discovery and delivery of medicine, leading to treatments that are safer, more precise, and more effective.

REFERENCE:

1. Zhavoronkov A, Ivanenkov YA, Aliper A, et al. Deep learning enables rapid identification of potent DDR1 kinase inhibitors. Nat Biotechnol. 2019;37(9):1038–1040.
2. Olivecrona M, Blaschke T, Engkvist O, Chen H. Molecular de-novo design through deep reinforcement learning. J Cheminform. 2017;9(1):48.
3. Polykovskiy D, Zhebrak A, Sanchez-Lengeling B, et al. Molecular sets (MOSES): A benchmarking platform for molecular generation models. Front Pharmacol. 2020;11:565644.
4. Akinc A, Maier MA, Manoharan M, et al. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nat Nanotechnol. 2019;14(12):1084–1087
5. Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6(12):1078–1094.
6. Eygeris Y, Patel S, Jozic A, Sahay G. Deconvoluting lipid nanoparticle structure for messenger RNA delivery. Nat Nanotechnol. 2022;17(8):953–961.
7. Zhang X, Pan Y, Li H, et al. Machine learning-guided lipid nanoparticle design for efficient mRNA delivery. Adv Drug Deliv Rev. 2023;200:114124.
8. Chen J, Xu H, Zou X, et al. AI-driven design of ionizable lipids for mRNA delivery. Nat Biomed Eng. 2024;8(2):152–165.
9. Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers (Basel). 2011;3(3):1377–1397.
10. Vamathevan J, Clark D, Czodrowski P, et al. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov. 2019;18(6):463–477.
11. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ. 2016;47:20–33.
12. Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov. 2010;9(3):203–214.
13. Rodrigues T, Schneider P, Schneider G. Counting on machine learning for drug design. Nat Chem. 2016;8(6):531–541.
14. Khateeb A, Fessi H, Elaissari A. mRNA-based therapeutics: challenges and future perspectives. Pharmaceutics. 2021;13(2):203.7.
15. Jumper J, Evans R, Pritzel A, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596(7873):583–58
16. Torchilin VP. Multifunctional hybrid nanocarriers for drug delivery. Nat Rev Drug Discov.2014;13(11):813–827
17. Ruan S, Yuan M, Zhang L, et al. Tumor microenvironment responsive nanoparticles for efficient cancer therapy. Nano Today. 2019;27:99–117.

18. Chauhan AS. Dendrimers for drug delivery. Molecules. 2018;23(4):938.

19. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004;303(5665):1818–1822.

20. 20. Badia A, et al. Artificial intelligence in lipid nanoparticle design for nucleic acid therapeutics. Adv Drug Deliv Rev. 2023;199:114908.

21. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25(1):44–56.

22. Wang D, et al. AI-enabled drug–nanocarrier interaction prediction for nanomedicine development. Small. 2021;17(15).

23. Monopoli MP, Aberg C, Salvati A, Dawson KA. Biomolecular coronas provide the biological identity of nanosized materials. Nat Nanotechnol. 2012;7(12):779–786.

24. Swinney, D. C., & Anthony, J. (2011). How were new medicines discovered? Nature Reviews Drug Discovery, 10(7), 507–519.

25. Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021). Engineering precision nanoparticles for drug delivery. Nature Reviews Drug Discovery, 20(2), 101–124.

26. Brown, E. D., & Wright, G. D. (2016). Antibacterial drug discovery in the resistance era. Nature, 529(7586), 336–343.